Randomized, double-blind, clinical trial of a polyvalent melanoma vaccine in patients with stage III melanoma.

被引：0
|
作者：
Bystryn, JC
Oratz, R
Shapiro, R
Harris, M
Roses, D
Jacquotte, A
机构：
[1] Kaplan Comprehens Canc Ctr, New York, NY USA
[2] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA
[3] NYU, Sch Med, Dept Med, New York, NY USA
[4] NYU, Sch Med, Dept Surg, New York, NY USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1998年 / 110卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [21] A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
    Cui, Chuanliang
    Mao, Lili
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Li, Siming
    Lian, Bin
    Gu, Kangsheng
    Tao, Min
    Song, Xin
    Lin, Tongyu
    Ren, Xiubao
    Qin, Shukui
    Guo, Jun
    MOLECULAR THERAPY, 2013, 21 (07) : 1456 - 1463
  • [22] A phase I trial with a hybrid cell vaccine in patients with metastatic melanoma.
    Trefzer, U
    Weingart, G
    Adrian, K
    Chen, Y
    Guo, YJ
    Audring, H
    Winter, H
    Walden, P
    Sterry, W
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (03) : 404 - 404
  • [23] Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)
    Hauschild, A.
    Eggermont, A. M.
    Jacobson, E.
    O'Day, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)
    Hauschild, A.
    Eggermont, A. M.
    Jacobson, E.
    O'Day, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [25] A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
    Linden, Kenneth G.
    Leachman, Sancy A.
    Zager, Jonathan S.
    Jakowatz, James G.
    Viner, Jaye L.
    McLaren, Christine E.
    Barr, Ronald J.
    Carpenter, Philip M.
    Chen, Wen-Pin
    Elmets, Craig A.
    Tangrea, Joseph A.
    Lim, Sung-Jig
    Cochran, Alistair J.
    Meyskens, Frank L., Jr.
    CANCER PREVENTION RESEARCH, 2014, 7 (05) : 496 - 504
  • [26] Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
    Chesney, Jason A.
    Ribas, Antoni
    Long, Georgina, V
    Kirkwood, John M.
    Dummer, Reinhard
    Puzanov, Igor
    Hoeller, Christoph
    Gajewski, Thomas F.
    Gutzmer, Ralf
    Rutkowski, Piotr
    Demidov, Lev
    Arenberger, Petr
    Shin, Sang Joon
    Ferrucci, Pier Francesco
    Haydon, Andrew
    Hyngstrom, John
    van Thienen, Johannes, V
    Haferkamp, Sebastian
    Guilera, Josep Malvehy
    Rapoport, Bernardo Leon
    VanderWalde, Ari
    Diede, Scott J.
    Anderson, James R.
    Treichel, Sheryl
    Chan, Edward L.
    Bhatta, Sumita
    Gansert, Jennifer
    Hodi, Frank Stephen
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 528 - +
  • [27] Long-term survival of stage IV melanoma patients treated with a polyvalent, shed antigen, melanoma vaccine
    Laky, D
    Shapiro, RL
    Harris, MN
    Roses, DF
    Jacquotte, AZ
    Reynolds, SR
    Bystryn, J
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (01) : 240 - 240
  • [28] Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma.
    Cunningham, C.
    Pavlick, A. C.
    Khan, K. D.
    Frenette, G.
    O'Day, S.
    Stephenson, J.
    Gonzalez, R.
    Yang, Z.
    Vrhovac, V.
    Uprichard, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 462S - 462S
  • [29] PHASE-I TRIAL OF SPECIFIC IMMUNOTHERAPY OF MELANOMA WITH A POLYVALENT MELANOMA ANTIGEN VACCINE
    BYSTRYN, JC
    LEVIN, M
    SPEYER, S
    HARRIS, M
    ROSES, D
    BERNSTEIN, P
    CLINICAL RESEARCH, 1984, 32 (02): : A574 - A574
  • [30] Prognostic biomarkers in stage II-III melanoma.
    Rizk, Emanuelle M.
    Gartrell, Robyn D.
    Chen, Andrew
    Chang, Rui
    Marks, Douglas K.
    Esancy, Camden L.
    Taback, Bret
    Horst, Basil A.
    Drake, Charles G.
    Rabadan, Raul
    Saenger, Yvonne M.
    CANCER RESEARCH, 2020, 80 (19) : 49 - 50
12345